| Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small cell lung cancer: a systematic review and meta analysis of randomized controlled trials. | |
| | |
MedLine Citation:
|
PMID: 22530708 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: To determine whether the cisplatin plus etoposide (EP) combination was more efficacious and less toxic than other platinum-based regimens for patients with extensive-stage small cell lung cancer (SCLC). METHODS: We performed a extensive literature search (from their inception to July 2010). Two reviewers independently assessed search results and methodological quality of included studies. Pooled hazard ratios (HR) and relative risks (RR) were calculated according to a random-effects model. RESULTS: 12 randomized control trials (RCTs) involving 7 different platinum-based chemotherapy regimens were included into this meta-analysis. The meta analysis showed that compared with EP regimen, irinotecan plus cisplatin (IP) might decrease the risk of death (HR=0.87, 95%CI: 0.78-0.97, P=0.01) (5 trials), unlike the sensitivity analysis (HR=0.91, 95%CI: 0.81-1.02, P=0.12), progression-free survival (HR=0.95, 95%CI: 0.86-1.05, P=0.28) and overall response rate (RR 1.08, 95%CI: 0.93-1.24) were not superior for IP. IP regimen produced more haematological toxicities and less non-haematological toxicities. One trial found PCDE (etoposide+cisplatin +epirubicin+cyclophosphamide) and EPI (cisplatin+etoposide+ifosfamide) regimen might prolong the overall survival (OS), respectivly. PCDE regimen also might improve PFS but with high rate of haematological toxicities. None of the other trials included in the study demonstrated a significant improvement in survival. CONCLUSIONS: There is no strong evidence that any clinical advantage for extensive SCLC patients requiring chemotherapy when comparing EP with other platin-based regimens, with exception of IP might prolong OS. The decision to prescribe which chemotherapy should take into consideration both cost and treatment preference. |
| | |
Authors:
|
Lei Jiang; Ke-Hu Yang; Quan-Lin Guan; Deng-Hai Mi; Jun Wang |
Related Documents
:
|
22442748 - Typical gastroduodenal endoscopic findings in a crohn's disease patient in remission st... 22537538 - Long-term outcomes of radiotherapy for stage ii testicular seminoma-the mayo clinic exp... 8993268 - Radical resection of radiation-induced sarcoma of the chest wall: report of 15 cases. 16131878 - De novo osteogenic sarcoma in patients older than forty: benefit of multimodality therapy. 10229598 - Occult cervical metastases: immunoperoxidase analysis of the pathologically negative neck. 12773228 - Management of bacillus calmette-guerin (bcg) refractory superficial bladder cancer: res... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-4-25 |
Journal Detail:
|
Title: Internal medicine journal Volume: - ISSN: 1445-5994 ISO Abbreviation: - Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-4-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101092952 Medline TA: Intern Med J Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2012 The Authors. Internal Medicine Journal © 2012 Royal Australasian College of Physicians. |
Affiliation:
|
Evidence based medicine center, Schoolschool of basic medical sciences, Lanzhou university, Lanzhou, China Department of Oncology Surgery, Thesurgery, the first hospital of Lanzhou university, Lanzhou, China. Oncology treatment center, Thethe second hospital of Gansu province, Lanzhou, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chitosan: a potential polymer for colon-specific drug delivery system.
Next Document: Office workers' sick building syndrome and indoor carbon dioxide concentrations.